VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, and nonalcoholic steatohepatitis; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; Alvogen Malta Operations (ROW) Ltd; and Janssen Pharmaceuticals, Inc. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone650-934-5200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$65.06 million
Profitability
Miscellaneous
Employees57
Next Earnings Date4/30/2019 (Confirmed)
OptionableOptionable
VIVUS (NASDAQ:VVUS) Frequently Asked Questions
What is VIVUS's stock symbol?
VIVUS trades on the NASDAQ under the ticker symbol "VVUS."
When did VIVUS's stock split? How did VIVUS's stock split work?
VIVUS's stock reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split.
How were VIVUS's earnings last quarter?
VIVUS, Inc. (NASDAQ:VVUS) released its earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.53) by $0.11. The biopharmaceutical company earned $20.11 million during the quarter. View VIVUS's Earnings History.
When is VIVUS's next earnings date?
Has VIVUS been receiving favorable news coverage?
Press coverage about VVUS stock has trended somewhat positive on Thursday, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. VIVUS earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of VIVUS's key competitors?
Some companies that are related to VIVUS include Aquestive Therapeutics (AQST), Tyme Technologies (TYME), AVEO Pharmaceuticals (AVEO), Chiasma (CHMA), Northwest Biotherapeutics (NWBO), Axovant Sciences (AXON), CytoDyn (CYDY), Eton Pharmaceuticals (ETON), Bellicum Pharmaceuticals (BLCM), Trevena (TRVN), Sol Gel Technologies (SLGL), Corvus Pharmaceuticals (CRVS), Chimerix (CMRX), Provention Bio (PRVB) and ASLAN PHARMACEU/ADR (ASLN).
What other stocks do shareholders of VIVUS own?
Who are VIVUS's key executives?
VIVUS's management team includes the folowing people:
- Mr. Mark K. Oki, Sr. VP, CFO & Chief Accounting Officer (Age 50)
- Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 54)
- Dr. Santosh T. Varghese, Chief Medical Officer (Age 49)
- Mr. John P. Amos, CEO & Director (Age 51)
- Mr. Ken Suh, Pres
How do I buy shares of VIVUS?
Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VIVUS's stock price today?
One share of VVUS stock can currently be purchased for approximately $3.67.
How big of a company is VIVUS?
VIVUS has a market capitalization of $39.04 million and generates $65.06 million in revenue each year. The biopharmaceutical company earns $-36,950,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. VIVUS employs 57 workers across the globe.
What is VIVUS's official website?
How can I contact VIVUS?
VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]
MarketBeat Community Rating for VIVUS (NASDAQ VVUS)
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
